Takeshi Kera1, Hisashi Kawai2, Hirohiko Hirano3, Motonaga Kojima4, Yutaka Watanabe5, Keiko Motokawa6, Yoshinori Fujiwara7, Yosuke Osuka8, Narumi Kojima9, Hunkyung Kim10, Kazushige Ihara11, Shuichi Obuchi12. 1. Takasaki University of Health and Welfare, Gunma, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: kera@takasaki-u.ac.jp. 2. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: hkawai@tmig.or.jp. 3. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: h-hiro@gd5.so-net.ne.jp. 4. University of Tokyo Health Sciences, Tokyo, Japan. Electronic address: m-kojima@u-ths.ac.jp. 5. Hokkaido University, Hokkaido, Japan. Electronic address: ywata@den.hokudai.ac.jp. 6. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: kikiki_1004@yahoo.co.jp. 7. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: fujiwayo@tmig.or.jp. 8. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: osuka@tmig.or.jp. 9. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: nkojima@centm.center.tmig.or.jp. 10. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: kimhk@tmig.or.jp. 11. Hirosaki University School of Medicine, Aomori, Japan. Electronic address: ihara@hirosaki-u.ac.jp. 12. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. Electronic address: obuchipc@tmig.or.jp.
Abstract
PURPOSE: The SARC-F is a recommended screening tool for sarcopenia; however, its sensitivity is reported to be very low. This study aimed to confirm the diagnostic efficacy of the SARC-F and whether it is affected by population characteristics. METHODS: In this study, 2 cohorts of 1060 community-dwelling older adults, who were monitored by the Tokyo Metropolitan Institute of Gerontology, were included. In addition to the overall dataset, receiver operating characteristic curve analysis was performed to obtain the SARC-F results for sarcopenia among the datasets for only those older in age (over 75 years), those with higher frailty points (above the median total score for the Kihon Checklist points), those with lower grip strength (below the median), lower gait speed (below the median), and those with comorbidities (hypertension, cerebral vascular disease, heart disease, and diabetes mellitus). RESULTS: In the overall dataset, sensitivity and specificity were 3.9% and 97.3%, respectively. In analyzing the area under the curve, sensitivity and specificity for older age and low physical function datasets were significant, but had low values. The diabetes dataset had higher values but did not effectively diagnose sarcopenia at a cutoff value of 4. CONCLUSION: The SARC-F had high specificity for the diagnosis of sarcopenia in community-dwelling older adults with low physical function. However, its sensitivity was low. Despite these limitations, it may be used as a screening tool for sarcopenia in selected populations, such as adults in hospitals or nursing homes.
PURPOSE: The SARC-F is a recommended screening tool for sarcopenia; however, its sensitivity is reported to be very low. This study aimed to confirm the diagnostic efficacy of the SARC-F and whether it is affected by population characteristics. METHODS: In this study, 2 cohorts of 1060 community-dwelling older adults, who were monitored by the Tokyo Metropolitan Institute of Gerontology, were included. In addition to the overall dataset, receiver operating characteristic curve analysis was performed to obtain the SARC-F results for sarcopenia among the datasets for only those older in age (over 75 years), those with higher frailty points (above the median total score for the Kihon Checklist points), those with lower grip strength (below the median), lower gait speed (below the median), and those with comorbidities (hypertension, cerebral vascular disease, heart disease, and diabetes mellitus). RESULTS: In the overall dataset, sensitivity and specificity were 3.9% and 97.3%, respectively. In analyzing the area under the curve, sensitivity and specificity for older age and low physical function datasets were significant, but had low values. The diabetes dataset had higher values but did not effectively diagnose sarcopenia at a cutoff value of 4. CONCLUSION: The SARC-F had high specificity for the diagnosis of sarcopenia in community-dwelling older adults with low physical function. However, its sensitivity was low. Despite these limitations, it may be used as a screening tool for sarcopenia in selected populations, such as adults in hospitals or nursing homes.
Authors: Tzyy-Guey Tseng; Chun-Kuan Lu; Yu-Han Hsiao; Shu-Chuan Pan; Chi-Jung Tai; Meng-Chih Lee Journal: Int J Environ Res Public Health Date: 2020-04-21 Impact factor: 3.390
Authors: Anna H Wu; V Wendy Setiawan; Unhee Lim; Chiu-Cheng Tseng; Kami K White; John Shepherd; Heinz Josef Lenz; Iona Cheng; Daniel O Stram; Christopher Haiman; Lynne R Wilkens; Loïc Le Marchand Journal: J Cachexia Sarcopenia Muscle Date: 2022-01-30 Impact factor: 12.910
Authors: Murat Kara; Bayram Kaymak; Walter Frontera; Ayşe Merve Ata; Vincenzo Ricci; Timur Ekiz; Ke-Vin Chang; Der-Sheng Han; Xanthi Michail; Michael Quittan; Jae-Young Lim; Jonathan F Bean; Franco Franchignoni; Levent Özçakar Journal: J Rehabil Med Date: 2021-06-21 Impact factor: 2.912